Group 1 - The company operates primarily in the pharmaceutical and health industry, focusing on pharmaceutical manufacturing, retail, research, and investment [3] - The company has approximately 128 drug production licenses, including 55 products listed in the national medical insurance directory [3] - The company has one new drug under research and five unique products or dosage forms nationwide [3] Group 2 - The company received a non-standard audit opinion from Beijing Dehao International Accounting Firm, indicating an inability to express an opinion on the financial report [2] - The company has not distributed cash dividends or bonus shares during the reporting period [2] - The company has initiated bankruptcy reorganization to address historical debt pressures and improve operational sustainability [6][7] Group 3 - The company is at risk of delisting due to its stock price being below 1 yuan for twenty consecutive trading days [8] - The Shenzhen Stock Exchange has issued a notice indicating the intention to terminate the company's stock listing [8]